Luis Rocha Lopes1, Dulce Brito2, Adriana Belo3, Nuno Cardim4. 1. Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom; Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, United Kingdom; Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Portugal. Electronic address: luis.lopes.10@ucl.ac.uk. 2. Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte (CHLN), Portugal. 3. Centro Nacional de Colecção de Dados em Cardiologia (CNCDC), Sociedade Portuguesa de Cardiologia, Portugal. 4. Hospital da Luz, Lisboa, Portugal; Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal.
Abstract
BACKGROUND: We present an ancillary study of the Portuguese Registry of Hypertrophic Cardiomyopathy (PRo-HCM). This is one of the largest HCM genetic studies based on a registry. METHODS AND RESULTS: Collected genetic variants were re-analysed for pathogenicity. Demographic, clinical, imaging and outcome data were analysed for associations with genotype, focusing on comparisons between patients with (G+) vs without (G-) a pathogenic/likely pathogenic (P/LP) variant in one the 9 main causal sarcomeric genes. From the 1042 patients in the registry, 528 (51%) had genetic testing. 152 (28%) were G+ and 98 pts. (19%) had variants of unknown significance. From the patients with the 9 mentioned genes sequenced (424 pts), 14.6% had P/LP variants in MYBPC3, 8.7% MYH7, 4.5% TNNT2, 1.7% TNNI3. Patients were 51 ± 16 years-old, 59% males. Genotype was associated with the following: birthplace (p = 0.005); age (p < 0.001); family history of HCM (p < 0.0005); hypertension (p < 0.0005); chest pain (p = 0.015); pattern of hypertrophy (p = 0.006); left ventricular hypertrophy on the ECG (p < 0.0005); family history of sudden cardiac death (SCD) (p = 0.002). G+ patients more frequently had more than one risk factor for SCD (p = 0.002) and a higher ESC-SCD risk score (p = 0.003). In survival analysis, G+ was associated with SCD (p = 0.017) and MYH7+ with LV systolic dysfunction (p = 0.038). CONCLUSION: Half of the registry patients had genetic testing. Sarcomere-positive patients had distinct demographics, ECG, imaging characteristics and family history and are at increased risk of SCD. The presence of a MYH7 mutation was associated with evolution towards LV systolic dysfunction.
BACKGROUND: We present an ancillary study of the Portuguese Registry of Hypertrophic Cardiomyopathy (PRo-HCM). This is one of the largest HCM genetic studies based on a registry. METHODS AND RESULTS: Collected genetic variants were re-analysed for pathogenicity. Demographic, clinical, imaging and outcome data were analysed for associations with genotype, focusing on comparisons between patients with (G+) vs without (G-) a pathogenic/likely pathogenic (P/LP) variant in one the 9 main causal sarcomeric genes. From the 1042 patients in the registry, 528 (51%) had genetic testing. 152 (28%) were G+ and 98 pts. (19%) had variants of unknown significance. From the patients with the 9 mentioned genes sequenced (424 pts), 14.6% had P/LP variants in MYBPC3, 8.7% MYH7, 4.5% TNNT2, 1.7% TNNI3. Patients were 51 ± 16 years-old, 59% males. Genotype was associated with the following: birthplace (p = 0.005); age (p < 0.001); family history of HCM (p < 0.0005); hypertension (p < 0.0005); chest pain (p = 0.015); pattern of hypertrophy (p = 0.006); left ventricular hypertrophy on the ECG (p < 0.0005); family history of sudden cardiac death (SCD) (p = 0.002). G+ patients more frequently had more than one risk factor for SCD (p = 0.002) and a higher ESC-SCD risk score (p = 0.003). In survival analysis, G+ was associated with SCD (p = 0.017) and MYH7+ with LV systolic dysfunction (p = 0.038). CONCLUSION: Half of the registry patients had genetic testing. Sarcomere-positive patients had distinct demographics, ECG, imaging characteristics and family history and are at increased risk of SCD. The presence of a MYH7 mutation was associated with evolution towards LV systolic dysfunction.
Authors: Jiří Bonaventura; Patricia Norambuena; Pavel Votýpka; Hana Hnátová; Radka Adlová; Milan Macek; Josef Veselka Journal: Cardiovasc Diagn Ther Date: 2020-04
Authors: Viktoria Höller; Heidelis Seebacher; David Zach; Nora Schwegel; Klemens Ablasser; Ewald Kolesnik; Johannes Gollmer; Gert Waltl; Peter P Rainer; Sarah Verheyen; Andreas Zirlik; Nicolas Verheyen Journal: Genes (Basel) Date: 2021-09-23 Impact factor: 4.096
Authors: Susan Christian; Allison Cirino; Brittany Hansen; Stephanie Harris; Andrea M Murad; Jaime L Natoli; Jennifer Malinowski; Melissa A Kelly Journal: Open Heart Date: 2022-04